Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Trevi Therapeutics (TRVI) Stock Price & Analysis
238 Followers
TRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.46 - $4.68
Previous Close$2.97
Volume130.91K
Average Volume (3M)120.65K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$125.60M
Total Debt (Recent Filing)$10.86M
Price to Earnings (P/E)-3.8
Beta0.98
Next EarningsMar 22, 2023
EPS Estimate-$0.1
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$7.67
EPS (TTM)-0.79
Shares Outstanding59,922,945
R-Squared0.00814
Standard Deviation0.47
10 Day Avg. Volume32,158
30 Day Avg. Volume120,653
Price to Book (P/B)1.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside158.25% Upside
Rating ConsensusStrong Buy
Alpha0.02
Number of Analyst Covering3
Trevi Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRVI FAQ
What was Trevi Therapeutics’s price range in the past 12 months?
Trevi Therapeutics lowest stock price was $0.46 and its highest was $4.68 in the past 12 months.
What is Trevi Therapeutics’s market cap?
Currently, no data Available
When is Trevi Therapeutics’s upcoming earnings report date?
Trevi Therapeutics’s upcoming earnings report date is Mar 22, 2023 which is in 44 days.
How were Trevi Therapeutics’s earnings last quarter?
Trevi Therapeutics released its earnings results on Nov 10, 2022. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.01.
Is Trevi Therapeutics overvalued?
According to Wall Street analysts Trevi Therapeutics’s price is currently Undervalued.
Does Trevi Therapeutics pay dividends?
Trevi Therapeutics does not currently pay dividends.
What is Trevi Therapeutics’s EPS estimate?
Trevi Therapeutics’s EPS estimate is -$0.1.
How many shares outstanding does Trevi Therapeutics have?
Trevi Therapeutics has 59,922,943 shares outstanding.
What happened to Trevi Therapeutics’s price movement after its last earnings report?
Trevi Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went up 1.036%.
Which hedge fund is a major shareholder of Trevi Therapeutics?
Among the largest hedge funds holding Trevi Therapeutics’s share is Fairmount Funds Management Llc. It holds Trevi Therapeutics’s shares valued at 9M.
---
Trevi Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67
$7.67
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 8.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
364.06%
12-Months-Change
Fundamentals
Return on Equity
-53.05%
Trailing 12-Months
Asset Growth
306.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
---
---